Skip to Main Content

A first-of-its-kind cancer treatment is generating unbridled excitement — but also underscoring intense concerns over pricing and value.

The drug, which is known as a CAR-T therapy, is expected to dramatically raise the chance of survival for children who have an aggressive form of leukemia and fail to respond to other treatments.


The $475,000 price tag is much less than Wall Street expected and might disappoint some investors who hoped for a premium on such a complex drug. But it’s still causing anxiety among patients. Mindful of the hit its reputation could take, Novartis is offering, in effect, a money-back guarantee: If a patient fails to respond in the first month, there will be no charge.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Sounds like Novartis have taken GcMAF, which the FDA closed down and intimidated and harassed doctors getting good results to then approve it for Novartis, at a difference in price in £ of £20,000 to £360,000. They are criminals that should be brought to justice. Why did the FDA do this? For money of course, what else!

  • Let’s cut down to the point. How much money is a child worth? That is the unethical question! People like Pierre Curie or Conrad Röntgen did not even file patents, as they deemed their Nobel Price inventions to valuable for man kind….. In our age and time they would be called fools I guess, or maybe our times are foolish?

Comments are closed.